Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Articles
Articles
Guidelines for Molecular/Cytogenetic Tests Can Eliminate Overordering, Reduce Costs
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
Instituting guidelines-based test ordering could lead to more effective, accurate, and complete diagnosis and monitoring of hematolymphoid malignancies, while reducing costs, according to hematopathologists at Vanderbilt University Medical Center, Nashville, who said that tests were frequently overordered by their hematologists.
Read More
Significant Cost of Treating Myeloproliferative Neoplasms
By
Neil Canavan
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
A new cost analysis of the management of the 3 subtypes of myeloproliferative neoplasms (MPNs)—myelofibrosis, polycythemia vera, and essential thrombocythemia—shows that associated medical and pharmaceutical expenses for patients with these hematologic disorders in patients with cancer are 2 to 6 times that of matched patients without cancer.
Read More
Serum-Based Immunoassay May Detect Pancreatic Cancer Early
GI Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—A serum-based enzyme immunoassay using the PAM4 antibody, combined with the serum marker CA19-9, detected stage I pancreatic cancer in nearly two thirds of patients analyzed in a study presented at the 2012 Gastrointestinal Cancers Symposium.
Read More
Regorafenib Extends Survival in Advanced CRC
By
Caroline Helwick
GI Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—The novel tyrosine kinase inhibitor (TKI) regorafenib, used as a single agent to treat treatment-refractory metastatic colorectal cancer (CRC), significantly improved survival and delayed disease progression in an international phase 3 trial presented at the 2012 Gastrointestinal Cancers Symposium.
Read More
Promising Data for New DNA Stool Testing, at Low Cost
GI Cancers Symposium
February 2012, Vol 3, No 1
>San Francisco, CA—The “eradication” of colorectal cancer (CRC) may be a step closer, based on promising data for stool DNA testing, said David A. Ahlquist, MD, Mayo Clinic, Rochester, MN, at the 2012 Gastrointestinal Cancers Symposium.
Read More
Building a National Patient Advocacy Network in Oncology
By
Rose Gerber
Patient Advocacy
,
Policies & Guidelines
February 2012, Vol 3, No 1
Read More
Patient Advocacy: A Physician’s Perspective
By
Richard Frame, MD
Patient Advocacy
,
Policies & Guidelines
February 2012, Vol 3, No 1
I never thought it would happen in the United States, but it has. We are critically close to running out of some chemotherapy drugs. It came as a shock to all of us, when we realized how severely the problem of drug shortages has started to affect our patients. The following case is but one example.
Read More
Paying for Quality: Increasing Shift Toward Value-Based Healthcare
Health Policy
,
Policies & Guidelines
February 2012, Vol 3, No 1
On November 30, 2011, the Office of the Inspector General (OIG) of the US Department of Health and Human Services issued an advisory opinion (No. 11-18) to the web-based physician practice service provider athenahealth, tacitly approving the company’s new online service athenaCoordinator.
Read More
Mammography Use Increases When Copays Are Dropped
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
February 2012, Vol 3, No 1
San Antonio, TX—When copayments were eliminated, annual screening mammography rates among insured rural women improved significantly, researchers from Duke University Comprehensive Cancer Center reported at the 2011 CTRC AACR San Antonio Breast Cancer Symposium.
Read More
The Health Burden of Multiple Myeloma: Subcutaneous Bortezomib a New, Convenient Route of Administration Option
By
Rhonda Williams
Cancer Drugs
,
Personalized Medicine
February 2012, Vol 3, No 1
In 2011, the American Cancer Society projected there would be 20,520 cases of newly diagnosed multiple myeloma (MM) and 10,610 deaths from the disease that year.
1
MM is an incurable hematologic cancer marked by great heterogeneity, in terms of its biology and clinical course.
Read More
Page 300 of 330
297
298
299
300
301
302
303
Top Trending Articles
1.
FDA Approves Acalabrutinib and Venetoclax Combination for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
2.
FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors
3.
FDA Launches Unified Adverse Event Monitoring System to Enhance Transparency and Efficiency
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma